Please login to the form below

Not currently logged in
Email:
Password:

Drug industry forms disaster response group

Rx Response, a programme designed to support the delivery of medicines during a disaster or severe public health emergency, was launched today by healthcare organisations involved in the manufacture, distribution and dispensing of pharmaceutical products

Rx Response, a programme designed to support the delivery of medicines during a disaster or severe public health emergency, was launched today by healthcare organisations involved in the manufacture, distribution and dispensing of pharmaceutical products.

Billy Tauzin, a former US representative from Louisiana, and now president and CEO of the Pharmaceutical Research and Manufacturers of America (PhRMA) said: "During a disaster, it is vital that systems are in place to assist with the continued delivery of medicines to hospitals, healthcare providers and patients in need."

In the past, when the pharmaceutical supply chain was disrupted, there was no single forum for suppliers to convene and share information. Rx Response will expedite information sharing among its partners, community volunteer relief organisations, as well as local, state and federal agencies responding to major disasters.

The partnership includes the American Hospital Association, American Red Cross, Biotechnology Industry Organisation, Healthcare Distribution Management Association, National Association of Chain Drug Stores, National Community Pharmacists Association and PhRMA.

30th September 2008

Share

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Onyx Health Ltd

Onyx Health is a healthcare communications and PR agency based in the North East of England, but with a national...

Latest intelligence

What’s in it for me? How to engage, motivate and support staff with internal training at OPEN Health
...
Environmental impact of in-person vs. virtual meetings
Although it will be tempting to resume in-person activities in the same capacity as before, we need to weigh the pros and cons of virtual vs. in-person vs. hybrid events...
US biosimilars
The US celebrates five years of biosimilars on the market – a look to the past, present and future
Why the success of biosimilars in the US has been mixed...

Infographics